Atrofia urogenital: seguridad del tratamiento con estrógenos vaginales / Safety of vaginal estrogens for urogenital atrophy
Rev. chil. endocrinol. diabetes
;
3(3): 208-210, jul. 2010.
Artigo
em Espanhol
| LILACS
| ID: lil-610321
ABSTRACT
Urogenital atrophy is characterized by dryness, inflammation, and thinning of the epithelial lining of the vagina and lower urinary tract due to estrogen decline. Local estrogen therapy if effective to relieve signs and symptoms of vaginal atrophy without causing an elevation of serum estrogen levels. Although there are no big studies addressing the safety of this type of treatment, it can be maintained over long periods to avoid annoying symptoms. Special care must be taken with women with breast cancer in whom the effective dose must be titrated to avoid an increase in serum estrogens over the levels usually observed in postmenopausal women.
Buscar no Google
Índice:
LILACS (Américas)
Assunto principal:
Estradiol
/
Estriol
/
Estrogênios
/
Doenças Urogenitais Femininas
Limite:
Feminino
/
Humanos
Idioma:
Espanhol
Revista:
Rev. chil. endocrinol. diabetes
Assunto da revista:
Endocrinologia
Ano de publicação:
2010
Tipo de documento:
Artigo
País de afiliação:
Chile
Instituição/País de afiliação:
Pontificia Universidad Católica de Chile/CL
Similares
MEDLINE
...
LILACS
LIS